Last reviewed · How we verify
Moxifloxacin / Dexamethasone Ophthalmic Solution
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone is a corticosteroid that reduces inflammation in the eye.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone is a corticosteroid that reduces inflammation in the eye. Used for Bacterial conjunctivitis, Post-operative ocular inflammation and infection, Corneal ulcers with bacterial infection.
At a glance
| Generic name | Moxifloxacin / Dexamethasone Ophthalmic Solution |
|---|---|
| Also known as | PRO-232 |
| Sponsor | Laboratorios Sophia S.A de C.V. |
| Drug class | Fluoroquinolone antibiotic + Corticosteroid combination |
| Target | Bacterial DNA gyrase, topoisomerase IV (moxifloxacin); Glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Moxifloxacin works by inhibiting bacterial DNA replication and repair enzymes, making it effective against a broad spectrum of ocular pathogens. Dexamethasone suppresses the inflammatory response by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene production. Together, this combination addresses both the infectious and inflammatory components of ocular conditions.
Approved indications
- Bacterial conjunctivitis
- Post-operative ocular inflammation and infection
- Corneal ulcers with bacterial infection
Common side effects
- Ocular irritation or discomfort
- Conjunctival hyperemia
- Increased intraocular pressure (with prolonged corticosteroid use)
- Taste perversion
- Photophobia
Key clinical trials
- PRO-232 in Patients Subjected to Cataract Surgery (PHASE3)
- Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PHASE1)
- Dropless Pars Plana Vitrectomy Study (PHASE4)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery (PHASE4)
- Topical Insulin Versus Autologous Serum After Corneal Surgeries (PHASE1)
- Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification (PHASE2)
- VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: